

The market landscape in developing SaMDs is changing rapidly in which stakeholders are increasingly looking for real world evidence (RWE) from code to commercialisation. Regulated software, classified as SaMDs, follow different pathways and understanding the evidence required for regulatory decision-making can be complex to navigate. Within this evolving environment, artificial intelligence and machine learning (AI/ML) is increasingly being used to enable SaMDs.
Come join us for this webinar where we will explore the increasing spotlight on the use of RWE, what regulators are looking for and how AI-powered applications are rising in the field of Digital Health from code to commercialisation.
Speakers:
Michelle Bulliard
Vice President, Real World Solutions MedTech
IQVIA
Brinda Sriskantha, PhD
Director, Real World Solutions MedTech
IQVIA
Robbert Zusterzeel, MD, PhD, MPH
Senior Director, Regulatory Science & Strategy
IQVIA
Nadea Leavitt
Senior Director, AI for Healthcare & MedTech
IQVIA
Suyin Lee
Manager, AI for Healthcare & MedTech
IQVIA